… Preterm infants, especially those with chronic lung disease (CLD), are considered more
susceptible to severe respiratory illness from respiratory syncytial virus (RSV) infection than …

… of palivizumab licensing for respiratory syncytial virus (… use of palivizumab and respiratory
syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus …

… Guidance from the American Academy of Pediatrics (AAP) for the use of palivizumab
prophylaxis against respiratory syncytial virus (RSV) was first published in a policy statement in …

… Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin
intravenous for the prevention of respiratory syncytial virus infections. Pediatrics 2003; 112…

… infants.14, 15 We hypothesized that the use of palivizumab in preterm infants, by ameliorating
or preventing early RSV LRTI, might decrease later recurrent wheezing. We report here on …

… Morbidity due to respiratory syncytial virus (RSV) disease is … RSV is the most common
cause of bronchiolitis in infants and … regarding appropriateness of palivizumab use in children …

… Respiratory syncytial virus (RSV) infection is a leading cause of hospitalisation in early
childhood and palivizumab is the only licensed intervention for prevention. Palivizumab …

… No significant anti-palivizumab antibodies developed during palivizumab use. Palivizumab
… about 33% and up to 14% of children prior to their second and third palivizumab injections. …

… to the FDA after palivizumab use, only 2% … palivizumab treatment were at increased risk
of death (CitationMohan 2004) and therefore no causal link has been established. Palivizumab …

… We hypothesize that the increased PVZ use is related to the known severity of RSV disease
in various vulnerable subpopulations and the desire to avoid additional morbidities. In …